Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD

BACKGROUND: CHF6001 is a novel inhaled phosphodiesterase-4 inhibitor. This Phase IIa study assessed the effects of CHF6001 on markers of inflammation in induced sputum and blood in patients with chronic obstructive pulmonary disease (COPD). METHODS: This was a multicentre, three-period (each 32 days...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Respir Res
Main Authors: Singh, Dave, Beeh, Kai Michael, Colgan, Brendan, Kornmann, Oliver, Leaker, Brian, Watz, Henrik, Lucci, Germano, Geraci, Silvia, Emirova, Aida, Govoni, Mirco, Nandeuil, Marie Anna
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6688371/
https://ncbi.nlm.nih.gov/pubmed/31399091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-019-1142-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados